Long COVID Fatigue and Brain Fog Linked to Dopamine Neuron Damage in New Brain Scan Study

In a brain imaging study published in the journal eBioMedicine in September 2026, researchers at the Centre for Addiction and Mental Health (CAMH) in Toronto identified a measurable neurological injury in patients suffering from long COVID. Using advanced positron emission tomography (PET) scans, the scientific team found a significant reduction in the nerve terminals responsible for releasing dopamine in the brain. The breakthrough findings offer a concrete biological mechanism for the persistent cognitive and physical symptoms that have frustrated both affected patients and their clinicians since the pandemic began, shifting the condition from a subjective syndrome to an observable structural deficit.[1][4]

Long COVID is estimated to affect roughly 5 percent of the global population, including approximately 2 million people in Canada alone. The condition is defined by a broad spectrum of symptoms—most notably profound fatigue, brain fog, and a severe loss of motivation—that persist for at least 3 months following an initial SARS-CoV-2 infection. Until now, the absence of objective biomarkers has made the syndrome difficult to measure, leaving many patients without targeted medical interventions and often struggling to have their symptoms fully validated by the medical establishment.[1][4]

To locate the source of the dysfunction, the CAMH researchers focused on 1 specific protein called vesicular monoamine transporter 2 (VMAT2). This protein sits on the endings of dopamine neurons and is responsible for packaging the neurotransmitter before it is released into the brain's neural pathways. By tracking a radioactive tracer designed to bind exclusively to VMAT2, the PET scans allowed the team to map the density of functional dopamine terminals across the brain without requiring any invasive tissue sampling.[2][4]

The imaging revealed that patients with confirmed long COVID had substantially lower VMAT2 density across 3 distinct sections of the striatum when compared to healthy control participants. A lower density of this protein indicates that the actual physical structures responsible for delivering dopamine on demand have been reduced. This represents a structural deficit in the dopamine system, rather than just a temporary daily fluctuation in the chemical's circulating levels, providing the first clear visual evidence of the injury.[2][4]

Crucially, the specific zones where dopamine terminals were depleted matched the exact symptoms reported by the patients during their clinical assessments. In the ventral striatum—a region governing reward anticipation and the drive to initiate behavior—lower VMAT2 levels correlated directly with a severe loss of motivation. Patients experiencing this specific deficit reported a profound lack of willpower to act, which the researchers noted is entirely distinct from general muscular weakness or standard physical exhaustion. It is a targeted failure of the brain's motivational circuitry.[1][2][3]

The anatomical pattern held true across other vital regions of the striatum. In the dorsal putamen, an area heavily involved in motor control and the fluid execution of physical actions, reduced terminal density was linked to noticeably slowed physical movement. Meanwhile, in the caudate putamen, a structure which supports executive cognitive function and the organization of working memory, the loss of VMAT2 correlated tightly with the memory difficulties and cognitive fog that are hallmarks of the post-viral condition. Each depleted zone corresponded to a different set of symptoms that clinicians previously could not measure.[1][2][4]

The direct correlation between the scans and the clinical presentations provides a new foundation for understanding the disease. "Our findings provide compelling evidence that long COVID involves the loss of dopamine-releasing neurons," said Dr. Jeffrey Meyer, Senior Scientist at the Brain Health Imaging Centre and the study's senior author. "This kind of injury is well known to produce symptoms like lack of motivation and motor slowing, and may contribute to memory difficulties in other neurological conditions. Our results suggest a similar process is occurring in long COVID."[3][4]

The current study builds upon 1 previous major investigation by the same CAMH team, which found unusually high levels of neuroinflammation in the brains of long COVID patients. That inflammation was heavily concentrated in the exact brain regions populated by dopamine-releasing neurons. The researchers hypothesize that the initial viral infection triggers a persistent inflammatory immune response, which in turn damages the highly vulnerable dopamine nerve terminals over time. This cascade effect ultimately leads to the prolonged and debilitating symptoms that patients experience for months or years.[1][3][4]

Identifying the dopamine system as the locus of injury fundamentally shifts the clinical approach to long COVID. For patients, this means their symptoms are grounded in a measurable structural deficit rather than a psychological hurdle. Because the dopamine pathway is already the primary target for treating conditions like Parkinson's disease, pharmacology in this area is well-established. Researchers are now looking at repurposing existing medications—such as dopamine precursors and inhibitors of dopamine metabolism—to see if boosting the remaining dopamine function can compensate for the lost terminals. However, clinicians caution against seeking off-label dopamine treatments before the upcoming trial confirms proper dosing and safety for this specific post-viral application.[1][2][4]

To test this hypothesis, the CAMH team is launching 1 dedicated clinical trial in collaboration with the University Health Network in the coming months. The trial will administer targeted dopamine therapies—using drugs already approved for other neurological conditions—to long COVID patients to measure whether pharmacological support can restore memory, motivation, and physical energy. If the intervention succeeds, it will provide the first prospective data showing that dopamine augmentation can return daily function to patients who have spent years waiting for a measurable diagnosis, with initial results anticipated by 2027.[2][3][4]